Ramosetron plus dexamethasone and aprepitant is as effective and tolerable as ondansetron in combination with dexamethasone and aprepitant for chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy, a new study published online ahead of print in the journal The Oncologist has shown.1
Ramosetron, like ondansetron, is a serotonin 5-HT3 receptor antagonist, used for the treatment of CINV in patients with cancer receiving highly emetogenic chemotherapy in Japan and other Southeast Asian countries. For the multicenter, single-blind, phase 3 study, researchers sought to compare ramosetron with ondansetron in combination with aprepitant and dexamethasone.
Researchers enrolled 299 patients with cancer and randomly assigned them to receive ramosetron or ondansetron intravenously plus aprepitant and dexamethasone orally.
Results showed that 97.2% of patients in the ramosetron group achieved a complete response during the acute phase, compared with 93.6% in the ondansetron arm. During the delayed phase, 77.8% and 73.6% of patients in the ramosetron and ondansetron arms, respectively, achieved a complete response.
Researchers found that ramosetron was superior to ondansetron in male patients.
In regard to tolerability, the safety profiles of both agents were similar.
“Ramosetron could be considered one of the best partners for aprepitant,” the authors conclude.
1. Kim HJ, Shin SW, Song EK, et al. Ramosetron versus ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21 [published online ahead of print October 28, 2015]. Oncologist. doi:10.1634/theoncologist.2015-0128.